Grifols (NASDAQ:GRFS) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.03 and traded as high as $8.03. Grifols shares last traded at $7.99, with a volume of 227,286 shares.

Analyst Ratings Changes

A number of brokerages recently commented on GRFS. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Weiss Ratings upgraded Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Grifols currently has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Trading Down 1.2%

The company’s 50 day moving average price is $7.61 and its two-hundred day moving average price is $8.02. The firm has a market cap of $5.44 billion, a PE ratio of 42.05, a P/E/G ratio of 0.29 and a beta of 0.66. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10.

Grifols Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio (DPR) is presently 42.11%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Bank of Montreal Can raised its holdings in shares of Grifols by 3,205.1% in the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after buying an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after acquiring an additional 2,221,633 shares during the last quarter. Norges Bank bought a new position in Grifols in the 4th quarter valued at $18,139,000. Brandes Investment Partners LP increased its stake in Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after purchasing an additional 1,838,727 shares during the period. Finally, Barclays PLC increased its stake in Grifols by 132.6% in the fourth quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after purchasing an additional 1,387,783 shares during the period.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.